Edesa Biotech, Inc.

NasdaqCM EDSA

Edesa Biotech, Inc. Net Cash Used Provided By Financing Activities for the year ending September 30, 2024: USD 592.03 K

Edesa Biotech, Inc. Net Cash Used Provided By Financing Activities is USD 592.03 K for the year ending September 30, 2024, a -87.74% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Edesa Biotech, Inc. Net Cash Used Provided By Financing Activities for the year ending September 30, 2023 was USD 4.83 M, a -58.47% change year over year.
Edesa Biotech, Inc. Net Cash Used Provided By Financing Activities for the year ending September 30, 2022 was USD 11.63 M, a -17.96% change year over year.
Edesa Biotech, Inc. Net Cash Used Provided By Financing Activities for the year ending September 30, 2021 was USD 14.17 M, a 99.85% change year over year.
Edesa Biotech, Inc. Net Cash Used Provided By Financing Activities for the year ending September 30, 2020 was USD 7.09 M, a 0.00% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: EDSA

Edesa Biotech, Inc.

CEO	Dr. Pardeep Nijhawan FRCPC, M.D.
IPO Date	June 21, 2010
Location	Canada
Headquarters	100 Spy Court
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Key trends

Past 5 years